• Home
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • Investors
  • Contact Us
Hillstream
  • Home
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • Investors
  • Contact Us
    Loading posts...

  • Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of QUATRAMER™ Drug Delivery Technology with HDAC6-PI3Kδ Dual Inhibitor for AML

    Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of QUATRAMER™ Drug Delivery Technology with HDAC6-PI3Kδ Dual Inhibitor for AML October 10, 2019 Chester, NJ –…
    October 10, 2019
    Announcement, Interview

  • Interview with Randy Milby, CEO

    Interview with Randy Milby, CEO April 5, 2019 This is the second post in an interview series with CEOs of small- to mid-cap companies, in which we ask them about products in…
    April 5, 2019
    Interview

Recent Posts

  • Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.
  • Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
  • Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis
  • Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
  • Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Address:

245 Main St., Ste. 204
Chester, NJ

Tel: +1 (917) 214-3514
Mail: info@hillstreambio.com
Hillstream Biopharma

1200 Route 22 East
Suite 2000
Bridgewater, NJ 08807

Tel: 1-908-955-3140
eMail: info@tharimmune.com

Latest News

  • Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. September 22, 2023
  • Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference September 21, 2023
  • Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis September 11, 2023

© Copyright 2023. Tharimmune, Inc. All Rights Reserved

Terms of use | Privacy Policy

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}